Roche Itovebi Gets European Commission Nod in Fight Against Advanced Breast Cancer

TF1 INFO

Center

Factuality

Ownership

On Wednesday, the European Commission authorised the placing on the market of Inavolisib, marketed as Itovebi, a treatment that combats advanced and metastatic forms of breast cancer. According to the studies carried out, the medicine reduces the risk of worsening the disease or death by 57%. - Breast cancer: a new treatment against advanced forms authorised by the EU (Health and well-being).

Le Parisien

Lean Right

Factuality

Ownership

Approved in October in the United States, this treatment of the Swiss pharmaceutical giant Roche is intended for a widespread subtype of the disease.

Le Singulier

Factuality

Ownership

The pharmaceutical giant Roche gets the EU's green light for its innovative drug, while a diagnostic test for Alzheimer's also receives a European certification. The Swiss laboratory Roche has announced a major breakthrough in the fight against breast cancer. The European authorities have approved the use of linavalisib, marketed under the name of Itovebi, [...] Read more A new treatment against authorised breast cancer in Europe appeared first …

MM Medical

Factuality

Ownership

Roche announced Tuesday that the European Commission has approved Itovebi (inavolisib) in combination with palbocilib and fulvestrant for the treatment of adult patients with locally advanced or metastatic breast cancer with a mutation in the gene.